2017 global paclitaxel market research overview

2017 Global Paclitaxel Market Research Overview Email: sale@qyresearch.com Tel:0086-20-86655165 http://www.qyresearch.com

2017 Global Paclitaxel Market Research Overview

1

Author: Zhang Xiao

Publisher: QYResearch

Published Date: May 27 2017

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy; Paclitaxel was discovered in 1962 as a

result of a U.S. National Cancer Institute-funded screening program; Monroe Wall and Mansukh Wani isolated the drug from the bark of the Pacific yew, Taxus brevifolia, and named it "taxol".

Global market of Paclitaxel developed rapidly, with an average growth rate of 14 %. In 2016, global revenue of Paclitaxel is nearly 62 million USD; the actual production is about 2000 Kg.

Paclitaxel is an anti-cancer “antineoplastic” or “cytotoxic” agent (commonly referred to as

chemotherapy) approved around the world and used primarily for the treatment of breast, ovarian, lung, bladder, prostate, melanoma, esophageal, as well as other types of solid tumor cancers. The most

proportion of Paclitaxel is used for Ovarian Cancer, and the Sales proportion is about 45.7% in 2016.

North America region is the largest supplier of Paclitaxel, with a production market share nearly 36.4% in 2016. China is the second largest supplier of Paclitaxel, enjoying production market share nearly 35.3% in 2016.

Market competition is intense. Phyton, ScinoPharm, Novasep, Samyang, etc. are the leaders of the industry.

2017 Global Paclitaxel Market Research Overview

2

Abraxane was developed by VivoRx which became Abraxis BioScience as the first in its class of drugs to use the nanoparticle albumin bound (nab) technology platform.

Sales of Abraxane® at Celgene were $973.4 million in 2016, up 0.6% from 2015. About two-thirds of the

sales are coming from the US, where Abraxane® controls 50-60% of the total paclitaxel injection market.

ABRAXANE® (paclitaxel albumin-bound particles for injectable suspension): ABRAXANE® is a solventfree chemotherapy product which was developed using proprietary nab® technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin.

This article was first released by QYResearch analyst, if reproduced, please indicate the source.

Media Contact: press@qyresearch.com Analyst : zhangxiao@qyresearch.com

2017 Global Paclitaxel Market Research Overview

3